Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Fortress Biotech shares rise after posting better-than-expected 2Q results on new drug advances

Fortress controls six biotech subsidiaries, including Mustang Bio and Checkpoint Therapeutics
Pills and bottles
The company's subsidiary Mustang Bio recently launched a Car-T cell manufacturing facility

The biopharmaceutical group Fortress Biotech Inc (NASDAQ:FBIO) saw its shares climb Friday after posting better-than-expected results for the second quarter helped by new drug advances from its subsidiaries.

The company came out with a loss of US$0.50 per share in the second quarter, or US$21.6mln, on revenue of US$63.83mln, which was a better performance than the loss of US$0.63 per share on revenue of US$49.78mln, which Wall Street had predicted.

In response, investors sent Fortress shares up 6.9% to US$2.28 in Friday’s morning trading session.

Compared to the year-ago quarter, however, the results look less impressive. The company’s net loss deepened when compared to its loss of US$17.4mln or US$0.43 in the same period last year.

Fortress looks to subsidiaries for revenue and victories in the lab

On the list of quarterly achievements from Fortress’s six subsidiaries was positive data from Avenue Therapeutics’ IV tramadol, which would be the only Schedule IV intravenous opioid in the US if approved.

Cyprium Therapeutics was also granted a fast-track designation by the Food and Drug Administration for its CUTX-101 Copper Histidinate injection in patients with Menkes disease, a rare pediatric disease.

Lastly, its subsidiary Mustang Bio Inc (NASDAQ:MBIO) launched a 27,000 square foot CAR-T cell manufacturing facility that will help to improve its supply-chain.

Read: Fortress Biotech subsidiary Aevitas Therapeutics enters into gene therapy research project with University of Pennsylvania

As of the close of June, Fortress had cash and cash equivalents of US$151.8mln, down from the US$168.3mln it reported at the close of December.

Based in New York, Fortress controls a number of biotech subsidiaries, including Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Checkpoint Therapeutics, Cyprium Therapeutics and Mustang Bio.

Its research and development expenses swung to US$17.5mln in the second quarter, of which US$15.1mln related to its subsidiaries.

Contact Ellen Kelleher at [email protected]

View full FBIO profile View Profile

Related Articles

chrome pipes
June 20 2018
Another change recently was for Tharisa to take over the running of the mine, which involved it buying the fleet from its contractor
Hong Kong harbour
September 17 2018
The transition of the business through the diversification of legacy assets and investing in new opportunities in Asia is well underway, said chairman John Croft
Picture of Malaysian city
May 09 2018
The group’s ability to provide benefits to the retail sector was demonstrated in 2017.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use